Cloud DX Прибыль на акцию Q/Q

Что обозначает Прибыль на акцию Q/Q в Cloud DX?

Прибыль на акцию Q/Q Cloud DX Inc. является N/A

Какое определение для Прибыль на акцию Q/Q?

Ежеквартальный темп роста прибыли на акцию, по сравнению с предыдущим кварталом, представляет собой увеличение прибыли на акцию компании за последние 4 квартала по сравнению с показателями за предыдущие 4 квартала.

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Что делает Cloud DX?

Cloud DX Inc. operates as a remote patient monitoring company. It offers Cloud DX Connected Health, an end-to-end virtual healthcare platform for monitoring patients with chronic illness, including chronic obstructive pulmonary disease and congestive heart failure, as well as patients recovering from surgery and COVID-19 patients outside hospitals. The company's Cloud DX Connected Health Kits includes its Cloud DX Bluetooth pulse oximeter, the Cloud DX wireless weight scale and optionally, a wireless Bluetooth blood pressure monitor, digital thermometer, and digital wireless glucose meter from 3rd party suppliers. It serves academic institutions, large hospitals, and provincial health authorities in Canada, as well as physician practices and hospitals in the United States. The company also offers VITALITI, a vital sign monitor for measuring electrocardiograph, heart rate, oxygen saturation, respiration, core body temperature, blood pressure, movement, steps, and posture. Cloud DX Inc. is headquartered in Brooklyn, New York.